文献速递妇产影像US

血管前置的筛查、诊断、管理与结局:单中心研究

Vasa previa screening, diagnosis, management and outcomes: single-center study.
PubMed 文献 · Ultrasound Obstet Gynecol · 2025-06-26

该单中心回顾性队列研究纳入2010年1月至2024年10月产前诊断的血管前置患者205例,采用孕中期经腹超声联合彩色多普勒筛查,孕32周经阴道超声确认。所有患者均行剖宫产,中位分娩孕周35.1周,围产期存活几乎普遍;36周及以上分娩的新生儿结局优于36周前分娩。作者强烈支持实施血管前置筛查方案,但不建议37周后分娩。

要点

  • 孕中期经腹超声识别脐带胎盘插入并彩色多普勒扫查宫颈,可有效筛查血管前置。
  • 孕中期低置胎盘或前置胎盘患者应常规行经阴道彩色多普勒超声检查。
  • 产前诊断血管前置后剖宫产分娩中位孕周为35.1周,围产期存活几乎普遍。

核心结论

  • 在常规筛查中心,产前诊断血管前置者围产期存活几乎普遍,作者强烈支持实施血管前置筛查方案,但不建议37周后分娩。

研究设计与样本

  • 回顾性队列研究,纳入美国波士顿贝斯以色列女执事医疗中心2010年1月至2024年10月产前诊断血管前置患者205例(189例单胎、16例双胎),常规孕中期经腹超声联合彩色多普勒筛查、孕32周经阴道超声确认。

诊断标准与关键数值

  • 孕中期经腹超声识别脐带胎盘插入并彩色多普勒扫查宫颈进行筛查;孕中期低置胎盘或前置胎盘者行经阴道彩色多普勒超声。
  • 所有诊断于孕约32周经阴道超声确认,据作者所知无假阳性或假阴性诊断。
  • 血管前置缓解25例(12.2%),分娩记录缺失6例,最终174例分娩时血管前置未缓解且均为产前诊断。

临床应用与阅片要点

  • 本研究中心常规在孕中期解剖扫查时经腹超声识别脐带胎盘插入并彩色多普勒扫查宫颈以筛查血管前置。
  • 本研究中心对孕中期低置胎盘或前置胎盘患者常规行经阴道彩色多普勒超声,并于孕约32周确认诊断。
  • 作者强烈支持实施血管前置筛查方案,认为其可能显著降低该病相关的高死产率。
  • 作者不建议37周后分娩。

局限性

  • 本研究为单中心回顾性队列研究。
  • 6例患者分娩记录不可用。
  • 唯一一例死亡发生于因双胎输血综合征接受激光凝固术的单绒毛膜双羊膜囊双胎之一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The aim of the present study was to describe the diagnosis, management and outcomes of patients with prenatally diagnosed vasa previa (VP) at a single center in which routine VP screening is performed.

METHODS: We carried out a retrospective cohort study of all patients with prenatally diagnosed VP at our institution (Beth Israel Deaconess Medical Center, Boston, MA, USA) between January 2010 and October 2024. We routinely screen all patients at the second-trimester anatomy scan by transabdominal ultrasound identification of the placental cord insertion and a color flow Doppler sweep over the cervix. We also routinely perform transvaginal ultrasound with color flow Doppler in all patients with a second-trimester low-lying placenta or placenta previa. We confirm all diagnoses in the third trimester, at approximately 32 weeks' gestation. Patients with VP were identified from the ultrasound and hospital databases. The primary outcome was perinatal survival in the screened patients, and we also compared neonatal outcomes between patients delivered < 36 or ≥ 36 weeks.

RESULTS: There were 205 patients (189 singleton and 16 twin gestations) with prenatally diagnosed VP during the study period. Resolution occurred in 25 (12.2%) patients, and delivery records were unavailable for six, leaving 174 patients with unresolved VP at delivery, all of whom were diagnosed prenatally. To our knowledge, there were no false-positive or false-negative diagnoses. All patients underwent Cesarean delivery, at a median gestational age of 35.1 (interquartile range, 34.6-35.9) weeks. All except one of the pregnancies resulted in live birth. The single death occurred in one of a set of monochorionic diamniotic twins that underwent laser photocoagulation for twin-twin transfusion syndrome. Delivery ≥ 36 weeks resulted in improved neonatal outcomes when compared with patients delivering < 36 weeks.

CONCLUSIONS: This study found almost universal perinatal survival in cases of prenatally diagnosed VP in a center with routine screening protocols for VP. These findings strongly support the implementation of a screening program for VP, which has the potential to significantly reduce the high rate of stillbirth associated with this condition. We do not, however, recommend delivery after 37 weeks' gestation. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lueck T, Macharia A, Modest A, et al. Vasa previa screening, diagnosis, management and outcomes: single-center study. Ultrasound Obstet Gynecol. 2025. PMID: 40569011. doi:10.1002/uog.29268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。